Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder - Botulinum toxin injection in non-neurogenic OAB

ational Center for Geriatrics & Gerontology0 个研究点目标入组 45 人开始时间: 2008年10月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) The patient has apparent neurogenic diseases causing urinary tract symptoms. 2) The patient underwent treatment with botulinum toxin A. 3) The patient underwent the surgery of lower urinary tract within 1 year. 4) Postvoid residual urine is 100ml or greater. 5) The patient has apparent lower urinary tract obstruction and/or weak detrusor. 6) Average voiding volume are 200ml or greater on frequency-volume chart. 7) The patient has stress urinary incontinence and/or functional urinary incontinence. 8) The patient has active urinary tract infection, malignance and/or bladder stone. 9) The patient is pregnant or breast-feed, or have possibility of such matter within 1 year. 10) The patient is diagnosed as having myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis. 11) The patient has disturbance of swallowing and/or respiration. 12) The patitent has mental and/or cognitive disturbance to conduct the clinical trial. 13) The patient is judged as being unsuitable for the trial by the researcher.

发起方

ational Center for Geriatrics & Gerontology